Who should be tested?
Testing for Alpha-1 is recommended by the American Thoracic Society for specific groups of patients. Testing for Alpha-1 is easy and can be done in your doctor’s office. Talk to your doctor about the free Talecris AlphaKit.
Learn who should be tested for Alpha-1.
Alpha-1 is a genetic condition that occurs when you inherit 2 copies of an abnormal gene from your parents. These genes control the production and distribution of the alpha1-antitrypsin (AAT) protein. When you have the 2 abnormal genes, you produce significantly less AAT than other people. In short, you are AAT-deficient and have Alpha-1.4
Alpha-1 occurs when a person inherits one abnormal gene from each of his or her parents.
Alpha-1 is one of the most prevalent potentially fatal hereditary diseases.1 While an estimated 100,000 Americans have Alpha-1, approximately 95% of them remain undiagnosed.2
Scientists have identified about 100 genes involved with the production and regulation of AAT.3 The most common abnormal gene is known as Proteinase inhibitor Z (Pi Z). You can get one copy from your mother and one from your father. When you inherit Pi Z from both your mother and father, they combine to form Pi ZZ, which results in Alpha-1.3
Since Alpha-1 is a genetic condition, there is always the potential for passing it on to children. Also, if one member of a family has a Pi Z gene, it raises the likelihood that other blood family members have it, too. If you have a single Pi Z gene, you are a carrier of the gene and might have a higher risk of developing lung disease.
Alpha-1 cannot be diagnosed using symptoms alone, but it is easy to diagnose with a simple blood test, which measures three factors for Alpha-1.
Ask your doctor about a free Talecris AlphaKit that can tell if you have Alpha-1.
Important Safety Information
Prolastin-C, Alpha1-Proteinase Inhibitor (Human) is for adults who have emphysema caused by inherited alpha1-antitrypsin deficiency. The effect of therapy with any alpha1-proteinase inhibitor (alpha1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Prolastin-C may contain trace amounts of IgA. IgA deficient patients with antibodies against IgA should not receive Prolastin-C due to the risk of hypersensitivity.
The most common side effects during clinical trials with Prolastin-C were chills, a general feeling of being unwell, headache, rash, hot flush, and itching.
Prolastin-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Please see accompanying Prolastin-C Full Prescribing Information for complete prescribing details.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.